Subsolid pulmonary nodules: CT-pathologic correlation using the 2011 IASLC/ATS/ERS classification

Clinical Imaging

Volumn 39, Issue 3, 2015, Pages 344-351

  Liao, Joseph H ^a   Amin, Vinit B ^a   Kadoch, Michael A ^a   Beasley, Mary B ^a   Jacobi, Adam H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma of lung; Ground glass nodules; Nonsolid nodules; Part solid nodules; Subsolid nodules

Indexed keywords

BIOLOGICAL ORGANS; DISEASES; MOLECULAR BIOLOGY; PATHOLOGY;

ADENOCARCINOMA OF LUNG; GROUND GLASS NODULES; NONSOLID NODULES; PART-SOLID NODULES; SUBSOLID NODULE;

COMPUTERIZED TOMOGRAPHY;

ADENOCARCINOMA IN SITU; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SURVEILLANCE; HISTOPATHOLOGY; HUMAN; LOW ENERGY RADIATION; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG ATYPICAL ADENOMATOUS HYPERPLASIA; LUNG INVASIVE ADENOCARCINOMA; LUNG MINIMALLY INVASIVE ADENOCARCINOMA; LUNG NODULE; MULTIFOCAL GROUND GLASS OPACITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOLOGICAL PARAMETERS; REVIEW; TUMOR GROWTH; TUMOR INVASION; TUMOR LOCALIZATION; ADENOCARCINOMA; CLASSIFICATION; EUROPE; INTERNATIONAL COOPERATION; LUNG TUMOR; MEDICAL SOCIETY; PATHOLOGY; PROCEDURES; RADIOGRAPHY; UNITED STATES;

ADENOCARCINOMA; EUROPE; HUMANS; INTERNATIONALITY; LUNG NEOPLASMS; SOCIETIES, MEDICAL; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 84927978207     PISSN: 08997071     EISSN: 18734499     Source Type: Journal    
DOI: 10.1016/j.clinimag.2014.12.009     Document Type: Review

References (43)

1. American Cancer Society Cancer facts & figure 2013 2013, American Cancer Society, Atlanta, GA, [Accessed at www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures 2013 on 12 January 2014].
2. Travis WD, Travis LB, Devesa SS Lung cancer. Cancer 1995, 75:191-202.
3. Humphrey L, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening for lung cancer: systematic review to update the U.S. Preventive Services Task Force recommendation statement. Evidence synthesis no. 105. AHRQ publication no. 13-05196-EF-1 2013, Agency for Healthcare Research and Quality, Rockville, MD.
4. Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011, 24:653-664.
5. Aoki T, Tomoda Y, Watanabe H, Nakata H, Kasai T, Hashimoto H, et al. Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology 2001, 220(3):803-809.
6. Moyer V Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014, 160(5):330-338.
7. Henschke CI, Yankelevitz DF, Mirtcheva R, McGuinness G, McCauley D, Miettinen OS ELCAP Group: CT screening for lung cancer-frequency and significance of part-solid and nonsolid nodules. AJR Am J Roentgenol 2002, 178:1053-1057.
8. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995, 75(12):2844-2852.
9. Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Naruke T, Suemasu K, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996, 201(3):798-802.
10. Ebright MI, Zakowski MF, Martin J, Venkatraman ES, Miller VA, Bains MS, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002, 74(5):1640-1646. [discussion 1646-7].
11. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E World Health Organization international histological classification of tumours. Histological typing of lung and pleural tumours 1999, in collaboration with Sobin LH and pathologists from 14 countries, Springer-Verlag. 3rd ed.
12. Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol 2006, 1(9):S13-S19.
13. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6(2):244-285.
14. Lee SM, Goo JM, Park CM, Lee HJ, Im JG A new classification of adenocarcinoma: what the radiologists need to know. Diagn Interv Radiol 2012, 18(6):519-526.
15. Weng S, Tsuchiya E, Satoh Y, Kitagawa T, Nakagawa K, Sugano H Multiple atypical hyperplasia of type II pneumocytes and bronchioloalveolar carcinoma. Histopathology 1990, 16:101-103.
16. Mori M, Rao SK, Popper HH, Cagle PT, Fraire AE Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod Pathol 2001, 14(2):72-84.
17. Yokose T, Doi M, Tanno K, Yamazaki K, Ochiai A Atypical adenomatous hyperplasia of the lung in autopsy cases. Lung Cancer 2001, 33:155-161.
18. Chapman AD, Kerr KM The association between atypical adenomatous hyperplasia and primary lung cancer. Br J Cancer 2000, 83(5):632-636.
19. Park CM, Goo JM, Lee HJ, Lee CH, Kim HC, Chung DH, et al. CT findings of atypical adenomatous hyperplasia in the lung. Korean J Radiol 2006, 7(2):80-86.
20. Kayser K, Nwoye JO, Kosjerina Z, Goldmann T, Vollmer E, Kaltner H, et al. Atypical adenomatous hyperplasia of lung: its incidence and analysis of clinical, glycohistochemical and structural features including newly defined growth regulators and vascularization. Lung Cancer 2003, 42:171-182.
21. Park BM, Cho MJ, Lee HS, Park DI, Park MR, Kim JO, et al. A case of atypical adenomatous hyperplasia of larger than 2 cm. Tuberc Respir Dis 2013, 74(6):280-285.
22. Borczuk AC Assessment of invasion in lung adenocarcinoma classification, including adenocarcinoma in situ and minimally invasive adenocarcinoma. Mod Pathol 2012, 25(Suppl. 1):S1-S10.
23. Jones KD Whence lepidic? The history of a Canadian neologism. Arch Pathol Lab Med 2013, 137:1822-1824.
24. Watanabe S, Watanabe T, Arai K, Kasai T, Haratake J, Urayama H Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography. Ann Thorac Surg 2002, 73(4):1071-1075.
25. Sakurai H, Dobashi Y, Mizutani E, Matsubara H, Suzuki S, Takano K, et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg 2004, 78(5):1728-1733.
26. Yim J, Zhu LC, Chiriboga L, Watson HN, Goldberg JD, Moreira AL Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol 2007, 20:233-241.
27. Maeshima AM, Tochigi N, Yoshida A, Asamura H, Tsuta K, Tsuda H Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator. J Thorac Oncol 2010, 5(3):333-339.
28. Kadota K, Yeh YC, D'Angelo SP, Moreira AL, Kuk D, Sima CS, et al. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Am J Surg Pathol 2014, 38(8):1118-1127.
29. Sugano M, Nagasaka T, Sasaki E, Murakami Y, Hosoda W, Hida T, et al. HNF4α as a marker for invasive mucinous adenocarcinoma of the lung. Am J Surg Pathol 2013, 37(2):211-218.
30. Sakao Y, Sakuragi T, Natsuaki M, Itoh T Clinicopathological analysis of prognostic factors in clinical IA peripheral adenocarcinoma of the lung. Ann Thorac Surg 2003, 75(4):1113-1117.
31. Sakao Y, Miyamoto H, Sakuraba M, Oh T, Shiomi K, Sonobe S, et al. Prognostic significance of a histologic subtype in small adenocarcinoma of the lung: the impact of nonbronchioloalveolar carcinoma components. Ann Thorac Surg 2007, 83(1):214-215.
32. Lim HJ, Ahn S, Lee KS, Han J, Shim YM, Woo S, et al. Persistent pure ground-glass opacity lung nodules ≥ 10 mm in diameter at CT scan: histopathologic comparisons and prognostic implications. Chest 2013, 144(4):1291-1299.
33. Vazquez M, Carter D, Brambilla E, Gazdar A, Noguchi M, Travis WD, et al. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. Lung Cancer 2009, 64(2):148-154.
34. Nakata M, Sawada S, Yamashita M, Saeki H, Kurita A, Takashima S, et al. Surgical treatments for multiple primary adenocarcinoma of the lung. Ann Thorac Surg 2004, 78(4):1194-1199.
35. Zwirewich CV, Miller RR, Muller NL Multicentric adenocarcinoma of the lung: CT-pathologic correlation. Radiology 1990, 176(1):185-190.
36. Girard N, Deshpande C, Lau C, Finley D, Rusch V, Pao W, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009, 33(12):1752-1764.
37. Barsky SH, Grossman DA, Ho J, Holmes EC The multifocality of bronchioloalveolar lung carcinoma: evidence and implications of a multiclonal origin. Mod Pathol 1994, 7(6):633-640.
38. Kim HK, Choi YS, Kim J, Shim YM, Lee KS, Kim K Management of multiple pure ground-glass opacity lesions in patients with bronchioloalveolar carcinoma. J Thorac Oncol 2010, 5(2):206-210.
39. Larke FJ, Kruger RL, Cagnon CH, Flynn MJ, McNitt-Gray MM, Wu X, et al. Estimated radiation dose associated with low-dose chest CT of average-size participants in the National Lung Screening Trial. AJR Am J Roentgenol 2011, 197(5):1165-1169.
40. Naidich DP, Bankier AA, MacMahon H, Schaefer-Prokop CM, Pistolesi M, Goo JM, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology 2013, 266(1):304-317.
41. Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, et al. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer 2012, 118(11):2889-2899.
42. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsch V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31(27):3327-3334.
43. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150(6):1107-1120.